Bioxytran

Bioxytran Liabilities

The The Liabilities of Bioxytran (BIXT) as of Nov 4, 2026 is 3.25 M USD. In the previous year, The Liabilities was 1.93 M USD — a change of 68.33% (higher).

Liabilities

3.25 MUSD

YoY

68.33%

Last updated:

In 2025, Bioxytran's total liabilities amounted to 3.25 M USD, a 68.33% difference from the 1.93 M USD total liabilities in the previous year.

The Bioxytran Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
261,725.00 USD
Jan 1, 2019
1.02 M USD
Jan 1, 2020
2.27 M USD
Jan 1, 2021
3.28 M USD
Jan 1, 2022
3.67 M USD
Jan 1, 2023
3.24 M USD
Jan 1, 2024
1.93 M USD
Jan 1, 2025
3.25 M USD
The Bioxytran Liabilities history
YEARLiabilitiesYoY
3.25 MUSD+68.33%
1.93 MUSD-40.49%
3.24 MUSD-11.55%
3.67 MUSD+11.91%
3.28 MUSD+44.53%
2.27 MUSD+122.56%
1.02 MUSD+289.31%
261,725.00USD+42.80%
183,278.00USD-46.45%
342,266.00USD+36.36%
251,000.00USD-25.01%
334,700.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioxytran Stock analysis

What does Bioxytran do? Bioxytran Inc. is a US-based company specialized in the development of medical therapies based on the use of oxygen transport molecules. The company's patented platform technology focuses on the development of new innovative therapies for treating central nervous system disorders, cardiovascular diseases, and cancer treatment. The company was founded in 2014 by a group of scientists and entrepreneurs aiming to create a transformative medical product that improves oxygen transport in the body and enables the treatment of severe diseases. Bioxytran's platform is based on the use of perfluorocarbon compounds (PFCs) that have a strong affinity for oxygen and can bind and transport it in the blood. The company's business model is centered on the development and commercialization of new therapies to treat diseases such as stroke, heart attack, cancer, and even COVID-19. By improving oxygen transport in the body, Bioxytran aims to enhance the effectiveness of medical treatments and create new therapeutic possibilities. The company's focus areas include stroke treatment, where they have developed a technology that allows direct oxygen transport to the affected brain tissue, minimizing neural damage and enabling faster recovery. They have also developed a new type of heart attack treatment that aims to improve blood flow and eliminate oxygen deficiency in the heart, as well as another therapy option for patients suffering from acute heart attacks. In the field of cancer treatment, Bioxytran has a promising therapy in the pipeline based on PFCs that can selectively target cancer cells, potentially making chemotherapy more effective and patient-friendly. Overall, Bioxytran's goal is to develop medical therapies that have the potential to revolutionize the treatment of severe diseases. They offer a range of products and approaches that have the potential to improve the lives of many patients. In summary, Bioxytran Inc. is an emerging company in the field of medical therapies, driven by innovation and technological expertise. Their focus on developing high-potential products that improve oxygen transport in the body facilitates the treatment of severe diseases. With their various divisions and products, Bioxytran is able to address a broad spectrum of medical needs. Bioxytran is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Bioxytran's Liabilities

Bioxytran's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Bioxytran's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Bioxytran's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Bioxytran's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Bioxytran’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Bioxytran stock

The Liabilities of Bioxytran is 3.25 M USD in 2025.

The Liabilities of Bioxytran changed from 1.93 M USD to 3.25 M USD, representing a 68.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Bioxytran since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Bioxytran historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioxytran

All Key Metrics — Bioxytran